Investigational drug · Phase 2
F573
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Liver Failure, Acute-On-Chronic Liver Failure.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "F573"
First trial start
2023
Mar 24, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "F573", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Liver Failure
- Acute-On-Chronic Liver Failure
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "F573" as an intervention, largest first.
- F573 Ia Clinical TrialPivotal-lookingCompleted
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT04820049 · 100 participants · Start Feb 8, 2021 · Primary completion Aug 2, 2022
Drug: F573 · For: Tolerance; Pharmacokinetic
Sites: Wuhan, China
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT05689645 · 97 participants (planned) · Start Mar 24, 2023 · Primary completion Sep 1, 2026
Drug: F573 for injection; Sterilizing water for injection · For: Acute Liver Failure; Acute-On-Chronic Liver Failure
Sites: Beijing, China; Qingyuan, China; Shiyan, China · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Comprehensive preclinical pharmacokinetics and metabolite profiling of a novel caspase inhibitor F573.
Gu Y, Ye X, Zhou S, et al. · Talanta 2026
- Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia.
Hu CL, Chen BY, Li Z, et al. · Cell Res 2022
- Pan-caspase inhibitor F573 mitigates liver ischemia reperfusion injury in a murine model.
Bral M, Pawlick R, Marfil-Garza B, et al. · PLoS One 2019
- Engraftment Site and Effectiveness of the Pan-Caspase Inhibitor F573 to Improve Engraftment in Mouse and Human Islet Transplantation in Mice.
Pepper AR, Bruni A, Pawlick R, et al. · Transplantation 2017
- Interactions of cAMP-mediated vasodilators with angiotensin II in rat kidney during hypertension.
Chatziantoniou C, Ruan X, Arendshorst WJ · Am J Physiol 1993
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.